Transverse myelitis
Posted On November 24, 2020
Transvere myelitis = TM
Differential diagnosis
- Compressive myelopathy: needs to be excluded by MRI
- ADEM: acute disseminated encephalomyelitis
- Acute demyelination involving brain and spinal cord
- MS: multiple sclerosis, separated by time and space
- NMO: neuromyelitis optica
- usually involves 3 or more vertebral segments
- Optic neuritis
- AQP4 Ab positive
- Poliomyelitis, post polio syndrome
- Spinal cord infarct
- Systemic autoimmune disorders:
- Sarcoidosis
- Sjogren’s syndrome
- SLE: lupus
- Less common:
- Ankylosing spondylitis
- Antiphospholipid Ab syndrome
- Behcet disease
- MCTD: mixed connective tissue disease
- Systemic sclerosis
- Paraneoplastic syndrome
General
- Rare disease
- Bimodal: more common in10-19 years old, 30-39 years old
- Subacute onset: average 2 days
- Idiopathic: about 60%
- Post infectious: such as enterovirus, varicella zoster, herpes virus, Listeria, hiv
- MRI: hyperintense signal, no compressive lesion, may show contrast enhancement
- CSF: abnormal in half of the patients:
- pleocytosis, some lymphocytes, usually < 100/microL
- protein usually around 75
- elevated IgG index
- Oligoclonal band usually neg. (unlike MS over 85% positive)
Subtypes
- Acute partial TM, risk of MS 60-90%
- Acute complete TM, risk of MS 5-10%
- longitudinally extensive, extends 3 or more vertebral segment
- Acute flaccid myelitis, symptoms of lower motor neuron involvement
Treatment
- Acute TM
- IV solumedrol 1 gram qd for 5 days
- Plasma exchange: 5 treatments every other day
- Aggressive cases: single dose of iv cyclophosphamide 800 to 1200 mg/m2
- Recurrent idiopathy TM: about 25 to 33 %
- Chronic immunomodulatory therapy:
- Mycophenolate 3 to 3 gram qd or
- iv rituximab 1000 mg every 6 months
- Chronic immunomodulatory therapy: